Aims: We performed a systematic review to evaluate stroke presentation, evaluation, management, and outcomes among studies conducted in low- and middle-income countries (LMIC). Methods: We searched MEDLINE (Ovid), Embase (Elsevier), and the Global Health (EBSCOhost) databases between January 2005 and June 2017 for studies conducted in LMICs defined by the World Bank. We pooled prevalence estimates using an inverse-variance weighting method and stratified by the country income group. Results: The search identified 36 hospital-based studies (64,256 participants) in LMICs. Mean (SD) age ranged from 51 (14) to 72 (12) years, and 29–56% of patients were women. Hypertension was the most commonly reported risk factor (64% [95% CI 59–69]). In settings where MRI was not used, head CT scans were reported among 90% patients (95% CI 79–97). Overall, 3% (95% CI 2–4) of patients were treated with tissue plasminogen activator, and 78% (95% CI 66–88) were treated with antiplatelet therapy. Overall, the rate of in-hospital mortality was 14% (95% CI 10–19), and the rate of in-hospital pneumonia was 17% (95% CI 14–20). Conclusions: Our review revealed the low use of evidence-based practices for acute stroke care in LMIC. The true use in hospitals that do not conduct this research is probably even lower. Strategies to evaluate and improve health system performance for acute stroke care, including implantation of stroke units and making thrombolysis more available and affordable are needed in LMIC. Registration in Prospero: CRD42017069325.

Keywords:
Stroke, Low- and middle-income countries, Acute care, In-hospital mortality, Evidence-based practice, Meta-analysis
1.
Feigin VL, Krishnamurthi RV, Parmar P, Norrving B, Mensah GA, Bennett DA, et al: Update on the global burden of ischemic and hemorrhagic stroke in 1990–2013: the GBD 2013 Study. Neuroepidemiology 2015; 45: 161–176.
2.
Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al: Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 2017; 70: 1–25.
3.
Schwamm LH, Pancioli A, Acker JE 3rd, Goldstein LB, Zorowitz RD, Shephard TJ, et al: Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association’s Task Force on the Development of Stroke Systems. Stroke 2005; 36: 690–703.
4.
Langhorne P, de Villiers L, Pandian JD: Applicability of stroke-unit care to low-income and middle-income countries. Lancet Neurol 2012; 11: 341–348.
5.
World Health Organization: from MDGs, millennium development goals to SDGs, sustainable development goals. World Health Organization 2015: 204. http://www.who.int/gho/publications/mdgs-sdgs/en/(accessedSeptember15, 2017).
6.
Lindsay P, Furie KL, Davis SM, Donnan GA, Norrving B: World Stroke Organization global stroke services guidelines and action plan. Int J Stroke 2014: 9(suppl A100): 4–13.
7.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006–1012.
8.
LMIC Filters: http://epoc.cochrane.org/lmic-filters. Cochrane Effective Practice and Organization of Care (EPOC) Group, 2013 (accessed 2017 May 23).
9.
World Bank Country and Lending Groups: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. World Bank, 2017 (accessed 2017 May 23).
10.
Search Filters for Various Databases: Ovid Medline. http://libguides.sph.uth.tmc.edu/search_filters/ovid_medline_filters. UTHealth School of Public Health, 2017 (accessed 2017 May 23).
11.
Ezejimofor MC, Chen YF, Kandala NB, Ezejimofor BC, Ezeabasili AC, Stranges S, Uthman OA: Stroke survivors in low- and middle-income countries: a meta-analysis of prevalence and secular trends. J Neurol Sci 2016; 364: 68–76.
12.
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.
13.
Callender T, Woodward M, Roth G, Farzadfar F, Lemarie JC, Gicquel S, et al: Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. PLoS Med 2014; 11:e1001699.
14.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–1587.
15.
Langhorne P, O’Donnell MJ, Chin SL, Zhang H, Xavier D, Avezum A, et al: Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study. Lancet 2018; 391: 2019–2027.
16.
Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, et al: Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med 2014; 371: 818–827.
17.
Kelly AG, Hellkamp AS, Olson D, Smith EE, Schwamm LH: Predictors of rapid brain imaging in acute stroke. Stroke 2012; 43: 1279–1284.
18.
Reeves MJ, Grau-Sepulveda MV, Fonarow GC, Olson DM, Smith EE, Schwamm LH: Are quality improvements in the get with the guidelines: stroke program related to better care or better data documentation? Circ Cardiovasc Qual Outcomes 2011; 4: 503–511.
19.
Abd-Allah F, Moustafa RR: Burden of stroke in Egypt: current status and opportunities. Int J Stroke2014; 9: 1105–1108.
20.
Uchino K, Man S, Schold JD, Katzan IL: Stroke legislation impacts distribution of certified stroke centers in the united states. Stroke 2015; 46: 1903–1908.
21.
Pandian JD, William AG, Kate MP, Norrving B, Mensah GA, Davis S, et al: Strategies to improve stroke care services in low- and middle-income countries: a systematic review. Neuroepidemiology 2017; 49: 45–61.
22.
Yan LL, Li C, Chen J, Miranda JJ, Luo R, Bettger J, et al: Prevention, management, and rehabilitation of stroke in low- and middle-income countries. eNeurologicalSci 2016; 2: 21–30.
23.
The WHO STEPwise approach to stroke surveillance. 0-version 1.2. World Health Organization. http://www.who.int/ncd_surveillance/en/steps_stroke_manual_v1.2.pdf. (accessed August 3, 2017).
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.